Agendia presents data from the innovative FLEX study at ASCO 2021, demonstrating the utility of MammaPrint and BluePrint to a broad category of patient groups

• ER+ breast cancer full transcriptome analysis showed that there was no significant difference in tumor gene expression in women under 50 vs.
women over 50 years of age
• Full transcriptome analysis confirmed that ER+ basal cell-like tumors vs.

ER-basal cell-like tumors BluePrint genome expression profile is very different Close, provide clinical actionable information to guide neoadjuvant treatment decisions

Precision Agendia, Inc.
ASCO

The FLEX study is led by clinicians across the United States, using shared research infrastructure, based on complete transcriptome data, establishing and exploring hypotheses for target patient subgroups, and recording more than 800 clinical data elements
.

FLEX helps various patient groups and their doctors to participate in a clinical trial, even if they do not live near a large research center

Dr.

Cynthia X.

At the ASCO 2021 online conference, Agendia and its research collaborators provided the latest in the current recruitment of FLEX trials in a poster titled " FLEX Real World Data Platform Exploring New Gene Expression Profiles in Early Breast Cancer and Research Projects Initiated by Researchers " Comprehensive information
.

FLEX real-world data platform explores new gene expression profiles of early breast cancer and research projects initiated by researchers

The poster data titled " Comparison of HR+HER2- Breast Cancer in Patients with <50 Years vs.
>50 Years Old " by Whole Transcriptome Analysis shows that FLEX has the ability to solve meaningful and urgent clinical problems .
The study showed that full transcriptome analysis did not detect significant differences in gene expression in HR+/HER2- breast cancer patients, regardless of their age (over 50 or under 50) .
The above data supports such a possible explanation: It has been observed in recent trials that chemotherapy for patients with genomic low-risk cancers under the age of 50 has significant age-dependent benefits, which cannot be attributed to the inherent biological differences of breast cancer, but Due to the difference in the indirect effects of chemotherapy on patients .
The above findings emphasize the necessity of sharing decision-making between patients and their doctors, and the patient's genome expression profile used is part of an informed treatment plan .

Full transcriptome analysis and comparison of HR+ HER2- breast cancer in patients <50 years old vs.

>50 years old

Cathy Graham, MD, FACS, Director of Breast Surgery, Glenn Family Breast Center, Winship Cancer Institute, Emory St.

Joseph Hospital, and first author of the FLEX poster focusing on age analysis, said: "We are very pleased to present the early breast cancer genomics According to age analysis, this type of cancer has attracted widespread attention in recent years

FLEX researchers presented additional data with clinical significance for high-risk ER+ breast cancer in a poster titled " The molecular profile of genomic high-risk ER+ HER2- breast cancer tumors is divided into functional basal cell-like or Luminal B type based on 80 gene characteristics ".

These investigators include Joyce O'Shaughnessy, MD , co-director of Breast Cancer Research, director of breast cancer prevention research at Baylor Sammons Cancer Center and American Cancer Network , and member of the American Cancer Research Network Scientific Advisory Board .

The molecular profile of genomic high-risk ER+ HER2- breast cancer tumors is divided into functional basal cell-like or Luminal B prevention based on 80 gene characteristics

An in-depth study of the FLEX database analyzed the correlation between the traditional pathological features of poor prognosis, namely lymphatic vascular infiltration (LVI) and gene expression patterns
.

The research titled " Gene expression associated with lymphatic vascular invasion and genomic risk in early breast cancer " was presented by Nina D'Abreo, MD, Medical Director of the Breast Project at the Perlmutter Cancer Center, Winthrop University Hospital, and colleagues.
It shows that the potential prognostic information obtained from the presence or absence of lymphatic vascular invasion (LVI) gene expression may have been captured by MammaPrint and BluePrint

Gene expression related to blood vessels and lymphatic vascular infiltration and genomic risk of early breast cancer

Agendia's large-sample, prospective FLEX study continues to provide rich data derived from real-world evidence.

This is one of the most dynamic and inclusive research designs in breast cancer research so far, highlighting that the company helps guide the diagnosis of all breast cancer patients And the mission of individualized treatment

diagnosis

About  Agendia

About  Agendia

Agendia is a precision oncology company headquartered in Irvine, California, dedicated to providing early-stage breast cancer patients and their doctors with the information they need to make the best decisions for the entire treatment process
.

The company currently provides two commercially available qualitative genomic tests.
These tests are supported by high-level clinical and real-world evidence.
They provide comprehensive genomic information and can be used to determine the most effective treatment for each breast cancer patient
.

MammaPrint® is a breast cancer recurrence test that covers 70 genes.
It is the only FDA- approved recurrence risk test, supported by peer-reviewed prospective outcome data and domestic and international treatment guidelines
.
BluePrint® is a molecular subtype test that covers 80 genes and is the only commercially available test solution that evaluates the basic biology of tumors to determine tumor growth drivers
.
The combined use of MammaPrint® and BluePrint® can provide comprehensive genome characterization, helping doctors make more informed decisions in preoperative and postoperative treatment
.

FDA

Agendia develops novel evidence-based genomic testing and has established partnerships with several pioneering companies to develop next-generation digital therapeutic tools
.
The ongoing research can establish a series of data to improve patient outcomes and meet the changing clinical needs of breast cancer patients and their doctors from initial diagnosis to cancer regression
.

Agendia's testing can rely on core biopsy or surgical specimens to issue doctor's orders, so as to provide a reference for preoperative and postoperative treatment decisions
.

Leave a message here